Market Research Report
Drug Delivery Products (US Market & Forecast)
|Published by||Freedonia Group||Product code||230864|
|Published||Content info||373 Pages
Delivery time: 1-2 business days
US demand for drug delivery products is forecast to grow 6.1 percent annually to $251 billion in 2019. Specialized dosage formulations that improve therapies for autoimmune, cancer, cardiovascular, neurological, viral, and other debilitating disorders will lead gains. Included in this group are human and humanized monoclonal antibodies, polymer-encapsulated medicines, and brachytherapy seeds. Among drug delivery devices, pen injectors and retractable prefillable syringes will record the fastest revenue growth based on safety, infection prevention, and ease-of-use advantages.
Demand for oral drug delivery products will benefit from bioavailability and reduced dosing advantages, while controlled-release formulations will continue to dominate revenues. On the downside, patent expirations and generic competition will soften overall growth potential for this product segment.
US demand for parenteral drug delivery products is projected to post double-digit gains through 2019. Advances in monoclonal antibodies and polymer-encapsulated medicines will underlie growth. The use of new and existing therapies based on human and humanized monoclonal antibodies will improve the effectiveness of remedies against various forms of cancer and other long-term disorders, such as allergy-linked asthma, Crohn's disease, rheumatoid and psoriatic arthritis, and wet age-related macular degeneration. Enhanced bioavailability and reduced toxicity advantages will boost applications for polymer-enhanced medicines in the treatment of conditions such as cancer complications, hepatitis B and C, and multiple sclerosis.
Among parenteral delivery devices, prefillable syringes will account for the largest and fastest expanding demand over the long term. Improvements in safety features such as automatic needle retraction, along with overall infection prevention and response time advantages, will benefit growth. Prefillable syringes will also broaden self-use applications based on advances in pen injectors and related apparatus.
Demand for other drug delivery products is expected to surpass $34 billion in 2019. Dry powder and metered dose inhalers will account for more than three-fourths of revenues, reflecting upward trends in prevalence of asthma and chronic obstructive pulmonary disease (COPD). On the downside, growth prospects for inhalers will weaken gradually as patent expirations make several widely used respiratory therapies -- such as ADVAIR, SPIRIVA and SYMBICORT -- available to low cost generic competition.
Limited indications and competition from alternative therapies will hold down demand for transdermal drug delivery products. Within this product group, overactive bladder and estrogen replacement therapies will post the fastest revenue growth. Contraceptive inserts will draw the largest and fastest expanding revenues among implantable drug delivery products based on convenience and effectiveness advantages in birth control applications. Brachytherapy implants will also fare well in the marketplace, spurred by increasing use in cervical, prostate, breast, and skin cancer treatment. Im-plantable drug pumps will see moderate growth in demand as improvements in device safety broadens applications in the delivery of pain control and ophthalmic medication. Recent introductions and a rise in heart conditions will foster growth in the market for drug-eluting stents.
Drug Delivery Products presents historical demand data (2004, 2009 and 2014) plus forecasts (2019 and 2024) by product and application. The study also assesses key market environment factors, examines the industry structure, analyzes company market share and profiles 30 US industry competitors.